AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15115249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Number of subjects: 9
Study 15115249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, hyperglycaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 12.0 mmol/L)
Number of subjects: 9
Study 15115249 — intervention group
Group type: COMPARATOR
Intervention: Standard clamp
Number of subjects: 9
Study 15115249 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp and Hyperinsulinaemic, hyperglycaemic clamp
Number of subjects: 9
Study 11257150 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and pulse cyclophosphamide (0.7 g/m2 at diagnosis) followed by either pulse or oral cyclophosphamide (2 mg/kg/day)
Number of subjects: 55
Study 11257150 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent ANCA
Number of subjects: 55
Study 11257150 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA reappearance
Number of subjects: 55
Study 11257150 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclophosphamide treatment
Number of subjects: 55
Study 11257150 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA negativity
Number of subjects: 55
Study 9481149 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the Well-being Questionnaire (WBQ)
Number of subjects: 105
Study 9481149 — intervention group
Group type: COMPARATOR
Intervention: Paper and pencil version of the Well-being Questionnaire (WBQ)
Number of subjects: 105
Study 9481149 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Number of subjects: 105
Study 9481149 — intervention group
Group type: COMPARATOR
Intervention: Paper and pencil version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Number of subjects: 105
Study 9481149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modes of assessment (WBQ and DTSQ)
Number of subjects: 105
Study 8149568 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive lens
Number of subjects: 25
Study 8149568 — intervention group
Group type: EXPERIMENTAL
Intervention: Front surface aspheric lens
Number of subjects: 25
Study 8149568 — intervention group
Group type: COMPARATOR
Intervention: Both lens types
Number of subjects: 25
Study 2901180 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (25 micrograms)
Number of subjects: 8
Study 2901180 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (50 micrograms)
Number of subjects: 8
Study 2901180 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (100 micrograms)
Number of subjects: 8
Study 2901180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28837949 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment style
Number of subjects: 103
Study 28837949 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance and anxiety attachment dimensions
Number of subjects: 103
Study 27127117 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30
Study 27127117 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 30
Study 27127117 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring activin A concentration
Number of subjects: 30
Study 27127117 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin concentration
Number of subjects: 30
Study 25002833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic supplementary nutrition support via gastrostomy immediately following placement
Number of subjects: 0
Study 25002833 — intervention group
Group type: COMPARATOR
Intervention: Usual care (nutrition support commenced via gastrostomy when clinically indicated during treatment)
Number of subjects: 0
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuplex D Plus (StD+), needle with improved echogenicity
Number of subjects: 15
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuplex A (StA), conventional needle
Number of subjects: 15
Study 22897671 — intervention group
Group type: COMPARATOR
Intervention: Human control (volunteer)
Number of subjects: 15
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Embalmed human cadaver
Number of subjects: 15
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork model
Number of subjects: 15
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkey model
Number of subjects: 15
Study 22897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic gel model
Number of subjects: 15
Study 20485955 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric 0.15% bupivacaine (3 mL, 4.5 mg)
Number of subjects: 150
Study 20485955 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric 0.6% lidocaine (3 mL, 18 mg)
Number of subjects: 150
Study 20485955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bupivacaine and lidocaine
Number of subjects: 150
Study 17573408 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 40
Study 17573408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15601276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Galileo ventilator
Number of subjects: 26
Study 15601276 — intervention group
Group type: COMPARATOR
Intervention: Drager CF 800
Number of subjects: 26
Study 12871461 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin E at 900 IU day(-1), vitamin C at 2000 mg day(-1)) for 6 weeks
Number of subjects: 24
Study 12871461 — intervention group
Group type: COMPARATOR
Intervention: Anti-beta(2) glycoprotein 1 (beta(2)GP(1)) antibodies
Number of subjects: 24
Study 12871461 — intervention group
Group type: COMPARATOR
Intervention: APL negative subjects (control group)
Number of subjects: 24
Study 10479199 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli diet (377 microg phylloquinone/d)
Number of subjects: 36
Study 10479199 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil diet (417 microg/d)
Number of subjects: 36
Study 10479199 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet only
Number of subjects: 36
Study 8571024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormonal contraceptive (gestodene 75 mcg + ethinylestradiol 30 mcg)
Number of subjects: 1321
Study 8339236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography with extended processing (Kopparberg part of the trial)
Number of subjects: 0
Study 8339236 — intervention group
Group type: COMPARATOR
Intervention: Two-view mammography with extended processing and grid (British Columbia screening program)
Number of subjects: 0
Study 3554985 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone for seven days plus sulfamethoxazole and trimethoprim for 30 days
Number of subjects: 52
Study 3554985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29274862 — intervention group
Group type: EXPERIMENTAL
Intervention: PMIR-UN (ultrasound guidance)
Number of subjects: 48
Study 29274862 — intervention group
Group type: COMPARATOR
Intervention: PMIR-CN (C-arm navigation)
Number of subjects: 48
Study 27160341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carotenoid fruit and vegetables (HCFV)
Number of subjects: 30
Study 27160341 — intervention group
Group type: COMPARATOR
Intervention: Low-carotenoid fruit and vegetables (LCFV)
Number of subjects: 30
Study 25455039 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin)
Number of subjects: 42
Study 25455039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 177
Study 23462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 177
Study 23462346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 177
Study 23462346 — intervention group
Group type: COMPARATOR
Intervention: Reports of abuse (physical, emotional, sexual)
Number of subjects: 177
Study 21563884 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal spatial attention
Number of subjects: 0
Study 21563884 — intervention group
Group type: COMPARATOR
Intervention: Distributed spatial attention
Number of subjects: 0
Study 19220966 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+HF group
Number of subjects: 77
Study 19220966 — intervention group
Group type: EXPERIMENTAL
Intervention: PE group
Number of subjects: 77
Study 19220966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 16534049 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (1 g) oral azithromycin
Number of subjects: 1452
Study 16534049 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for household members (20 mg/kg up to 1 g) plus the patient
Number of subjects: 1452
Study 16534049 — intervention group
Group type: COMPARATOR
Intervention: Topical tetracycline (twice per day for 6 weeks)
Number of subjects: 1452
Study 12919237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 335
Study 10673249 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg/d for 1 month
Number of subjects: 10
Study 10673249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10673249 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study 8951438 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous contralateral white noise at varying levels (10 dB below to 10 dB above the click level)
Number of subjects: 0
Study 8951438 — intervention group
Group type: EXPERIMENTAL
Intervention: Click levels at peak sound pressures of 50, 55, 60, 65 and 70 dB
Number of subjects: 0
Study 1790067 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin (750 mg/12 h/orally)
Number of subjects: 64
Study 1790067 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (500 mg/8 h)
Number of subjects: 64
Study 6805497 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparietal diameter (BPD) measurements known to obstetricians
Number of subjects: 1062
Study 6805497 — intervention group
Group type: COMPARATOR
Intervention: Biparietal diameter (BPD) measurements withheld from obstetricians
Number of subjects: 1062
Study 31718662 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0
Study 31718662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28719717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) at 50 mg twice a week for 3 weeks
Number of subjects: 30
Study 28719717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (Cialis) at 20 mg twice a week for 3 weeks
Number of subjects: 30
Study 28719717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra) at 20 mg twice a week for 3 weeks
Number of subjects: 30
Study 25839920 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI records
Number of subjects: 1310
Study 25839920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tonsil position measurement
Number of subjects: 1310
Study 24558764 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise in thermal mineral water
Number of subjects: 72
Study 24558764 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise therapy
Number of subjects: 72
Study 21296244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope (BL)
Number of subjects: 21
Study 21296244 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 21
Study 21296244 — intervention group
Group type: COMPARATOR
Intervention: Viewmax laryngoscope
Number of subjects: 21
Study 21296244 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 21
Study 21296244 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices except Macintosh
Number of subjects: 21
Study 19244540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (D(2) antagonist)
Number of subjects: 0
Study 19244540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulpiride and L-dopa
Number of subjects: 0
Study 19244540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19244540 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 0
Study 16723324 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate GAI scores
Number of subjects: 1105
Study 16723324 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate VCI scores
Number of subjects: 1105
Study 16723324 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate POI scores
Number of subjects: 1105
Study 15637825 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview with the physician
Number of subjects: 270
Study 15637825 — intervention group
Group type: COMPARATOR
Intervention: Self‐administered survey
Number of subjects: 270
Study 11246096 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage class and support group
Number of subjects: 34
Study 11246096 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 34
Study 9224839 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 1 - Reaching and grasping with varying distances of the second target.
Number of subjects: 0
Study 9224839 — intervention group
Group type: COMPARATOR
Intervention: Experiment 2 - Movements directed towards spatial locations at different distances without a near second target.
Number of subjects: 0
Study 9224839 — intervention group
Group type: COMPARATOR
Intervention: Experiment 3 - Reaching and grasping with and without a second near stimulus.
Number of subjects: 0
Study 8114834 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 322
Study 8114834 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 322
Study 3046815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine, 40 microliters applied in the lower cul-de-sac of one eye
Number of subjects: 8
Study 3046815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 31782534 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 13
Study 31782534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study 30192928 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose scopolamine (0.2 mg IV)
Number of subjects: 0
Study 27492015 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 110 mg/m2 on day 1 and 100 mg/m2 on day 8 plus cisplatin 80 mg/m2 on day 8 every 3 weeks (IC arm)
Number of subjects: 124
Study 27492015 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m2 plus cisplatin 80 mg/m2 on day 1 every 3 weeks (PC arm)
Number of subjects: 124
Study 27492015 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin (PC)
Number of subjects: 124
Study 25475357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg in divided doses)
Number of subjects: 85
Study 25475357 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 85
Study 23292661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic bone aspirator (UBA)
Number of subjects: 130
Study 23292661 — intervention group
Group type: COMPARATOR
Intervention: Traditional steel instrumentation
Number of subjects: 130
Study 21252212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMNs)
Number of subjects: 0
Study 21252212 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron/folic acid
Number of subjects: 0
Study 21252212 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 0
Study 18435948 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1544
Study 18435948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1544
Study 17098095 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20
Study 17098095 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 14662281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 866
Study 14662281 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.5 mg respectively)
Number of subjects: 866
Study 14662281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 10962638 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 0
Study 8957972 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% caudal bupivacaine 0.5 ml kg‐1 and diamorphine 30 micrograms kg‐1
Number of subjects: 45
Study 8957972 — intervention group
Group type: COMPARATOR
Intervention: 0.25% caudal bupivacaine 0.5 ml kg‐1 alone
Number of subjects: 45
Study 1309179 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 20
Study 1309179 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube (TT)
Number of subjects: 20
Study 3911482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) initial dose 240 U (anti F Xa)/kg/12 h in study I; 120 U (anti F Xa)/kg/12 h in study II
Number of subjects: 29
Study 3911482 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) initial dose 240 U/kg/12 h in both studies
Number of subjects: 29
Study 3911482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 29
Study 31422507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise programme (2 days/week, 60 min/session; independent home exercises 3 days/week, ≥ 20 min/session)
Number of subjects: 19
Study 31422507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise programme
Number of subjects: 19
Study 31422507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study 30343028 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA-ICS
Number of subjects: 12366
Study 30343028 — intervention group
Group type: COMPARATOR
Intervention: LAMA
Number of subjects: 12366
Study 26852337 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 28
Study 26852337 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminders
Number of subjects: 28
Study 23899894 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (8 mg)
Number of subjects: 9
Study 23899894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22342714 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine citrate
Number of subjects: 71
Study 22342714 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 71
Study 22342714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study 20799043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute strenuous exercise
Number of subjects: 8
Study 20799043 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum exposure 1 hour post-exercise
Number of subjects: 8
Study 20799043 — intervention group
Group type: COMPARATOR
Intervention: Autologous serum exposure
Number of subjects: 8
Study 16873380 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone
Number of subjects: 120
Study 16873380 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone
Number of subjects: 120
Study 16873380 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 40 mg and 80 mg doses
Number of subjects: 120
Study 16271643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 15 mg intravenous then 200 mg oral daily; n=22,929)
Number of subjects: 45852
Study 16271643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=22,923)
Number of subjects: 45852
Study 11907616 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 317
Study 11907616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 10453854 — intervention group
Group type: EXPERIMENTAL
Intervention: 70%/30% heliox
Number of subjects: 23
Study 10453854 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 23
Study 7869554 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP
Number of subjects: 497
Study 7869554 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 497
Study 7869554 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial combinations of PRP-OMP and HbOC
Number of subjects: 497
Study 7869554 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconjugated PRP
Number of subjects: 497
Study 7869554 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 497
Study 2404480 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg/d for 14 days
Number of subjects: 100
Study 2404480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 334227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (50-200 mg daily)
Number of subjects: 24
Study 334227 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50-225 mg daily)
Number of subjects: 24
Study 30770291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 54 Gy in three 18 Gy fractions or 48 Gy in four 12 Gy fractions if the tumor was <2 cm from the chest wall.
Number of subjects: 101
Study 30770291 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy - 66 Gy in 33 daily 2 Gy fractions or 50 Gy in 20 daily 2.5 Gy fractions, depending on institutional preference.
Number of subjects: 101
Study 28017642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ebola vaccine at 4·0×1010 viral particles (low dose)
Number of subjects: 120
Study 28017642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ebola vaccine at 1·6×1011 viral particles (high dose)
Number of subjects: 120
Study 28017642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120